Lineage Cell Therapeutics Inc (NYSE American:LCTX)
| 1.48 Delayed Data As of Dec 02 |  0.00 / 0.00%Today’s Change | 1.02 Today|||52-Week Range 2.71 | -39.59% Year-to-Date |
Latest LCTX News | Press Releases
No recent news for Lineage Cell Therapeutics Inc.
Today’s Trading
| Previous close | 1.48 |
| Today’s open | 1.47 |
| Day’s range | 1.44 - 1.49 |
| Volume | 235,332 |
| Average volume (3 months) | 340,439 |
| Market cap | $249.9M |
Data as of 3:59pm ET, 12/02/2022
Growth & Valuation
| Earnings growth (last year) | -90.04% |
| Earnings growth (this year) | +41.21% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +404.01% |
| P/E ratio | NM |
| Price/Sales | 103.45 |
| Price/Book | 2.70 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XXII22nd Century Group I... | 0.00 | 0.00% |
| VYGRVoyager Therapeutics... | +0.38 | +6.29% |
| ---- | ||
| OTLKOutlook Therapeutics... | +0.03 | +2.86% |
Data as of 4:00pm ET, 12/02/2022
Financials
| Next reporting date | March 16, 2023 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $3.9M |
| Annual profit (last year) | -$43.0M |
| Net profit margin | -1,104.18% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Carlsbad, California |
Forecasts
